Doctor Riccardo Perfetti
New York (United States of America)
Diabetic Cardiomyopathy: baseline Characteristics of patients enrolled into the ARISE-HF trial
Event: Heart Failure 2023
Topic: Comorbidities
Session: ePosters in chronic heart failure - comorbidities 3
Beneficial effects of AT-001, an aldose reductase inhibitor, in rodent models of diabetic cardiomyopathy
Event: Heart Failure 2019
Topic: Comorbidities
Session: Clinical Forum - Sat.25 May 08:30 - Tues. 28 May at 12:30
Safety and proof of biological activity support clinical development of AT-001 for diabetic cardiomyopathy: a phase 1/2 study
Event: Heart Failure 2019
Topic: Comorbidities
Session: Clinical Forum - Sat.25 May 08:30 - Tues. 28 May at 12:30
ESC 365 is supported by
